Awards recognize CluePoints’ Risk-Based Monitoring solution in the ‘Best Sponsor-Focused Technological Development’ category.
Cambridge, MA – CluePoints, a leading software provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has been named a finalist in the ‘Best Sponsor-Focused Technological Development’ category for the 2016 Clinical Research & Excellence (CARE) Awards. The company’s SaaS Central Statistical Monitoring solution for RBM and data quality oversight has been shortlisted for the inaugural awards which take place in Boston on 27 April 2016.
The CARE Awards provides the industry with an opportunity to acknowledge and applaud its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement. CluePoints software has been implemented by leading pharmaceutical companies and CROs as the engine to drive RBM, providing broad risk mitigation and patient safety through complete data quality oversight. The value of the solution lies in its ability to identify anomalous patient data and site discrepancies allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
“Our customers rely on us to deliver solutions that put them in complete control of their centralized monitoring and data quality oversight. As a result, users now have the ability to independently and objectively identify anomalies in data earlier, offering the opportunity to eradicate issues as they are uncovered”, commented Patrick Hughes, Chief Commercial Officer, CluePoints. “The CARE Awards recognition of our software supports our continued efforts, and that of our customers and partners, to advance RBM and we are honored that our technology has been acknowledged among the best solutions in the industry.”
For further information on CluePoints’ solutions, please visit www.cluepoints.com
About CluePoints
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a risk-based monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
Media contact:
Patrick Hughes – Chief Commercial Officer, CluePoints
[email protected]
+44 (0) 7703 532 749
